Skip to main content

Kyverna Therapeutics, Inc.

corporate_fare Company Profile

Kyverna Therapeutics, Inc.

KYTX·NASDAQ·Life Sciences·CIK 0001994702

We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Our lead product candidate is mivocabtagene autoleucel, or miv-cel (also known as KYV-101), an anti-CD19 autologous CAR T with a differentiated CAR construct. We have experience treating more than 100 autoimmune patients with miv-cel, documented through scientific publications of autoimmune case studies, our proprietary dataset from compassionate use, ongoing investigator-initiated trials (IITs) at academic institutions, and early clinical data from our company-sponsored trials. These therapies aim to deeply deplete B cells to achieve durable treatment-free remission. Miv-cel is an autologous, fully human CD19-targeting CAR T-cell product candidate designed for potency and tolerability in autoimmune diseases. The underlying chimeric antigen receptor (CAR) for miv-cel is licensed from the National Institutes of Health (NIH). This CAR includes a fully human scFv domain, a human CD8α hinge and transmembrane domain, a human CD28 costimulatory domain, and a human CD3ζ activation domain. The same underlying CAR in miv-cel completed a 20-patient Phase 1 clinical trial in oncology conducted by the NIH. Results from this trial, published in Nature Medicine, reported similar rates of durable antitumor responses and improved tolerability in adult oncology patients compared to the CAR used to create Yescarta®.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for KYTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Kyverna Therapeutics Activates $100M At-The-Market Offering, Enabling Significant Share Sales
  • Kyverna Therapeutics Files New $300M Universal Shelf Registration, Including $100M At-The-Market Offering
  • Kyverna Therapeutics Reports Positive Clinical Milestones, Secures Funding for Runway into 2028, and Remediates Internal Control Weaknesses
  • Kyverna Therapeutics Secures $147.5M, Extends Runway into 2028, Advances Lead CAR T Programs
  • Kyverna Targets 1H 2026 BLA for Stiff Person Syndrome Drug After Landmark Trial Data; Cash Secured into 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$161.31M
Diluted EPS
-$3.64
Op. Cash Flow
-$153.71M
Free Cash Flow
-$153.72M
Operating Income
-$169.83M
Cash & Equivalents
$124.09M
Debt / Equity
0.00×
Shares Outstanding
60.39M sh
Source: 10-K · filed 2026-03-26 · accession 0001193125-26-126242
$4.18 -1.88% today
52-week range · as of 2026-11-12 $4.18 – $13.67
Market cap
$269.33M
Volume
1.3M (1.6× avg)
3-mo avg 856.7K
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KYTX - Filings & News (Page 2)

KYTX
Apr 02, 2026, 4:48 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $8.74
Real-time Price: $4.18 info
Change: -$4.56 (-52%) info
Market Cap: $269.326M info
KYTX
Mar 26, 2026, 4:22 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $8.24
Real-time Price: $4.18 info
Change: -$4.06 (-49%) info
Market Cap: $269.326M info
KYTX
Mar 26, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $8.24
Real-time Price: $4.18 info
Change: -$4.06 (-49%) info
Market Cap: $269.326M info
KYTX
Mar 26, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.24
Real-time Price: $4.18 info
Change: -$4.06 (-49%) info
Market Cap: $269.326M info
KYTX
Mar 26, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.14
Real-time Price: $4.18 info
Change: -$3.96 (-49%) info
Market Cap: $269.326M info
KYTX
Feb 24, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.91
Real-time Price: $4.18 info
Change: -$3.73 (-47%) info
Market Cap: $269.326M info
KYTX
Feb 03, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.97
Real-time Price: $4.18 info
Change: -$3.79 (-48%) info
Market Cap: $269.326M info
KYTX
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.31
Real-time Price: $4.18 info
Change: -$4.13 (-50%) info
Market Cap: $269.326M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets